China Jul 21, 2019
In the past year, torrential rains have dumped water on U.S. farmlands, destroying acreage and delaying crops from getting planted on time. Now, farmers face another hurdle: a stifling heat wave that’s spreading across the United States and is expected to be the worst in the farm regions, including Oklahoma, Kansas, Nebraska, Missouri, Iowa and Illinois. “Every time we think. Chicago Jul 8, 2019
The work of famed American architect Frank Lloyd Wright was recognized Sunday as eight of his buildings, including the Solomon R. Guggenheim Museum in New York City, Los Angeles’ Hollyhock House and the Unity Temple in suburban Chicago, were added to the UNESCO World Heritage list.
AOP Orphan reports full validity of arbitral award against PharmaEssentia
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
AOP Orphan reports full validity of arbitral award against PharmaEssentia
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
BESREMi® (Ropeginterferon alfa-2b) deemed safe and efficacious by the US FDA
BESREMi® (Ropeginterferon alfa-2b) deemed safe and efficacious by the US FDA
Wien (pts026/15.03.2021/15:15) -
The US Food & Drug Administration (FDA) issued a complete response letter for the drug BESREMi® with the active pharmaceutical ingredient Ropeginterferonalfa-2b, in which the FDA confirms the efficacy and safety of the drug. This assessment was based on the clinical development program by the European rare disease company AOP Orphan.
On March 12, 2021, according to PharmaEssentia Corp., the FDA in the United States issued a so-called Complete Response Letter in respect to the submission of BESREMi® (Ropeginterferonalfa-2b) for the treatment of polycythaemia vera, a rare form of blood cancer. The Complete Response Letter confirms the safety and efficacy of BESREMi® in compliance with FDA regulations. The Complete Response Letter comes almost a year after PharmaEssentia s application to t